The global AI in neurology market size was estimated at USD 760.0 million in 2025 and is projected to reach USD 4.5 billion by 2033, growing at a CAGR of 24.9% from 2026 to 2033. The market is experiencing rapid expansion, driven by the increasing global prevalence of neurological disorders and the growing emphasis on early diagnosis, precision medicine, and data-driven clinical decision-making. Conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, stroke, and brain tumors are becoming more common as populations age and awareness improves, creating strong demand for advanced technologies that can assist healthcare professionals in detecting and managing these complex disorders more effectively.
Artificial intelligence is playing an increasingly important role in neurology by enabling the analysis of large volumes of clinical, imaging, and physiological data with greater speed and accuracy. AI-powered algorithms can identify subtle abnormalities in magnetic resonance imaging (MRI), computed tomography (CT), electroencephalography (EEG), and other diagnostic tests, supporting neurologists in diagnosing diseases at earlier stages and developing more personalized treatment plans. These capabilities are particularly valuable in neurology, where early detection and precise characterization of disease progression are critical for improving patient outcomes and optimizing therapeutic interventions.
The growing focus on precision medicine is further accelerating adoption, as AI technologies help integrate genetic information, biomarker data, imaging findings, and patient histories to tailor treatment strategies to individual patients. By uncovering patterns that may not be readily apparent through conventional analysis, AI supports more accurate prognostic assessments and enables clinicians to select therapies based on a patient’s specific neurological profile.
In addition, the increasing adoption of remote monitoring solutions is contributing significantly to market growth. Wearable devices, mobile health applications, and connected sensors can continuously collect data on movement, sleep, cognition, and seizure activity, allowing AI systems to monitor disease progression and detect clinically relevant changes in real time. These technologies are particularly beneficial for chronic neurological conditions that require long-term observation and frequent assessment outside traditional healthcare settings.
Key Market Trends & Insights
• North America dominated the global AI in neurology market and accounted for the largest revenue share of 52.5% in 2025. The region’s leadership is driven by advanced healthcare infrastructure, strong adoption of artificial intelligence technologies, significant investments in neurological research, and the presence of leading medical technology and software companies. Hospitals, academic medical centers, and research institutions across North America are increasingly deploying AI-powered tools to support early diagnosis, neuroimaging analysis, treatment planning, and remote patient monitoring. Favorable regulatory developments, robust funding for digital health innovation, and high awareness of neurological disorders continue to strengthen the region’s dominant position.
• Based on application, the neuroimaging and diagnostics segment led the market with the largest revenue share of 36.0% in 2025. This segment accounted for the highest share due to the extensive use of artificial intelligence to analyze magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and electroencephalography (EEG) data. AI algorithms help identify subtle abnormalities, automate image interpretation, and support more accurate and timely diagnosis of conditions such as stroke, Alzheimer’s disease, brain tumors, and multiple sclerosis. The growing demand for faster and more precise diagnostic capabilities is driving continued adoption in this segment.
• Based on neurological condition, the stroke segment led the market with the largest revenue share of 26.8% in 2025. Stroke remains one of the most time-sensitive neurological emergencies, where rapid diagnosis and treatment are critical to minimizing long-term disability and mortality. AI solutions are widely used to detect large vessel occlusions, assess brain perfusion, and prioritize urgent cases for clinical review. Their ability to accelerate image analysis and assist treatment decisions has made stroke one of the most prominent applications for AI in neurology.
• Based on component, the software segment led the market with the largest revenue share of 58.0% in 2025. Software solutions form the core of AI in neurology by providing machine learning algorithms, clinical decision support tools, imaging analysis platforms, and predictive analytics applications. These platforms can be integrated with hospital information systems, picture archiving and communication systems (PACS), and electronic health records to deliver real-time insights and workflow automation. The scalability and continuous advancement of software technologies are supporting strong growth in this segment.
• Based on end use, the hospitals and clinics segment led the market with the largest revenue share of 57.7% in 2025. Hospitals and clinics are the primary settings for diagnosing and treating neurological disorders, making them the largest adopters of AI-enabled tools. These healthcare providers use artificial intelligence to enhance diagnostic accuracy, improve treatment planning, optimize patient monitoring, and streamline clinical workflows. Increasing investments in digital infrastructure and growing emphasis on delivering timely and personalized neurological care continue to drive adoption within this segment.
Looking for more specific insights? Customize this report to suite your business needs
Key AI in Neurology Company Insights
Key companies operating in the global AI in neurology market are actively pursuing strategic initiatives such as partnerships, product launches, collaborations, acquisitions, and research alliances to strengthen their technological capabilities and expand their presence in the rapidly evolving healthcare landscape. These initiatives are playing a crucial role in fostering innovation and accelerating the development and deployment of artificial intelligence solutions designed specifically for neurological applications.
By forming partnerships with hospitals, academic institutions, imaging centers, pharmaceutical companies, and research organizations, market participants are able to access large and diverse neurological datasets that are essential for training and validating advanced machine learning algorithms. These collaborations support the development of highly accurate tools for neuroimaging analysis, disease prediction, treatment planning, and remote patient monitoring. They also help companies ensure that their solutions are clinically relevant and aligned with the needs of neurologists and healthcare providers.
New product launches are another important strategic focus, with companies introducing AI-powered platforms and software applications that assist in the diagnosis and management of conditions such as stroke, Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, and brain tumors. These solutions often incorporate advanced image analysis, predictive analytics, and clinical decision support capabilities to improve diagnostic accuracy, reduce time to treatment, and enhance patient outcomes.
Collaborations and acquisitions enable companies to integrate complementary technologies, expand their intellectual property portfolios, and accelerate commercialization. For example, acquisitions of specialized AI developers, neuroinformatics companies, and digital health firms help larger organizations strengthen their capabilities in algorithm development, cloud deployment, and regulatory compliance. Collaborative agreements also facilitate the integration of AI tools into hospital systems, electronic health records, and imaging workflows, making adoption more seamless for healthcare providers.
Collectively, these strategic initiatives are fostering continuous innovation and helping to bring more sophisticated and clinically validated AI solutions to market. As stakeholders across the healthcare ecosystem increasingly recognize the potential of artificial intelligence to transform neurological care, partnerships, launches, collaborations, and acquisitions are expected to remain central to the growth and advancement of the AI in neurology market throughout the forecast period.
Key AI in Neurology Companies:
The following key companies have been profiled for this study on the AI in neurology market.
• Cortechs.ai
• Viz.ai
• RapidAI (trademarks of iSchemaView, Inc)
• Aidoc
• Brainomix
• Avicenna.AI
• Natus
• Hyperfine
• PERSYST DEVELOPMENT LLC
• Ceribell, Inc.
• Empatica Inc.
• GE Healthcare
• Koninklijke Philips N.V.
• Siemens Healthiness
Grand View Research offers
√ Focused market intelligence reports on specific geographies or high-growth segments.
√ Extended forecast timelines for long-term planning.
√ Competitor Benchmarking and Supply Chain Analysis
√ Inclusion of regulatory and policy assessments.
√ Inclusion of custom data models, KPIs, or applications unique to your business
√ Specific high-impact Data Decks and Tables to support effective decision making
And much more…
Looking for a report customized to your requirements? Explore our Custom Research Offering